# Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

> **NCT03935555** · PHASE1 · TERMINATED · sponsor: **Samus Therapeutics, Inc.** · enrollment: 11 (actual)

## Conditions studied

- Primary Myelofibrosis (PMF)
- Post-Polycythemia Vera Myelofibrosis (Post-PV MF)
- Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

## Interventions

- **DRUG:** PU-H71

## Key facts

- **NCT ID:** NCT03935555
- **Lead sponsor:** Samus Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-12
- **Primary completion:** 2022-10-19
- **Final completion:** 2022-11-04
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Samus Therapeutics company closure
- **Last updated:** 2022-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03935555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03935555, "Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03935555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*